ArticlePLOS global public health2025
Characteristics and six-month viral load suppression of clients presenting with advanced HIV disease in South Africa.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in antiretroviral therapy (ART), a notable proportion of individuals still present with advanced HIV disease (AHD) at treatment initiation, defined by CD4 < 200 cells/µL or WHO stage 3/4. This group experiences higher mortality and more opportunistic infections. While guidelines exist, they often do not address AHD clients specific needs early in treatment. Addressing these gaps could improve outcomes. Between September 2022 and June 2023, we surveyed a sequential sample of clients initiating ART or ≤6 months post-initiation at 18 primary healthcare facilities across three provinces. This observational cohort collected socio-demographic data, HIV care history, and service delivery preferences, and linked surveys to routine medical records and described client characteristics using descriptive statistics. Relative risks and risk differences compared outcomes between AHD and non-AHD clients. Primary outcomes were 6-month retention and viral load suppression. Of 1,098 clients (72% female, median age 33), 938 had CD4 or WHO staging at ART start. Of these, 29% (n = 275) had AHD, with a median CD4 of 108 cells/µL. AHD clients were more often male (44% vs. 21%), older (median age: 38 vs. 31 years), and sought care due to illness (63% vs. 33%). TB diagnosis (42% vs. 12%) and testing (76% vs. 67%) were higher. Service preferences and health resource use were similar. Retention at 6 months was similar (80% vs. 75%), but mortality was higher in AHD clients (1.0% vs. 0.2%). AHD clients had more low-level viremia (24% vs. 11%; RR = 2.27, 95% CI = 1.67-3.09) and slightly lower suppression (43% vs. 47%). AHD remains a key barrier to optimal ART outcomes. Clients with AHD experienced poorer viral suppression, despite similar retention rates highlighting the need for early detection, tailored clinical support, and strengthened monitoring. Updating ART guidelines to address AHD-specific needs is critical to improving outcomes in this high-risk population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.